drugset / Trial / NCT02216513
Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
Phase 0
Terminated
2 enrolled
Brigham and Women's Hospital
Dr. Jeffrey Thomas Stroke Shield Foundation · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant against delayed ischemic injury after SAH.
Timeline
- Start
- 2014-09
- Primary completion
- 2015-06
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Deferoxamine | Other / unclassified | 20 mg/kg | Intravenous |